Valuation: Alvotech

Market Cap 1.37B 1.19B 1.11B 1.02B 1.93B 130B 1.95B 13.08B 5.11B 65.17B 5.15B 5.03B 216B P/E 2026 *
14.5x
P/E 2027 * 8.38x
Enterprise Value 2.45B 2.13B 1.99B 1.83B 3.45B 233B 3.49B 23.42B 9.16B 117B 9.22B 9.01B 387B EV / Sales 2026 *
3.74x
EV / Sales 2027 * 3.07x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day+1.32%
Current month-59.06%
Current year-59.06%
5 years 3.78
Extreme 3.785
10.44
10 years 3.78
Extreme 3.785
11.62
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
9/21/20 A OthersCompany 218,750 3.8889%
9/16/20 A OtherCompany 0 0%
9/16/20 A OtherCompany 6,468,750 115.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%+23.87% - - 1.35B
-0.68%-0.68%-1.63%+12.86% 48.22B
+6.03%+5.22%+420.33%+519.87% 38.79B
-2.21%-6.07%+24.87%+5.20% 38.41B
+2.94%-2.25%+6.15%+59.69% 34.88B
+1.98%+4.74%+12.19%+41.37% 29.19B
+0.47%-3.87% - - 16.05B
+0.31%+0.72%+32.99%+122.25% 16B
+1.59%+0.44%+3.43%+16.80% 13.53B
-0.98%-12.98%-4.82%-38.09% 12.22B
Average +1.08%+0.01%+61.69%+92.49% 27.48B
Weighted average by Cap. +1.21%+1.55%+78.99%+112.40%

Financials

2026 *2027 *
Net sales 656M 570M 531M 488M 923M 62.43B 933M 6.26B 2.45B 31.21B 2.46B 2.41B 103B 793M 688M 642M 589M 1.11B 75.38B 1.13B 7.56B 2.96B 37.68B 2.98B 2.91B 125B
Net income 91.8M 79.71M 74.32M 68.27M 129M 8.73B 131M 876M 343M 4.36B 345M 337M 14.46B 151M 131M 123M 113M 213M 14.4B 215M 1.44B 565M 7.2B 568M 556M 23.85B
Net Debt 1.08B 941M 877M 806M 1.52B 103B 1.54B 10.34B 4.04B 51.52B 4.07B 3.98B 171B 1.07B 925M 862M 792M 1.5B 101B 1.51B 10.17B 3.97B 50.65B 4B 3.91B 168B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
04/08/26 $3.840 +1.32% 575,289
03/08/26 $3.790 -8.01% 1,026,989
31/07/26 $4.120 +15.41% 1,721,179
30/07/26 $3.570 +1.13% 989,695
29/07/26 $3.530 +13.87% 3,036,187
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.840USD
Average target price
5.750USD
Spread / Average Target
+49.74%

Quarterly revenue - Rate of surprise